Lead Product(s): Antibody drug conjugates
Therapeutic Area: Oncology
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Iksuda Therapeutics
Deal Size: $407.3 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 16, 2020
The agreement grants Iksuda an access to Legochem Biosciences’ next-generation payload and proprietary linker to discover and advance lead ADC for difficult-to-treat tumours.